deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT03663335

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (CIRRUS I)

A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)

Sponsor: Novartis Pharmaceuticals

Conditions Kidney Transplant Rejection
Interventions CFZ533 - MMF - CS Tacrolimus - MMF - +/- corticosteroids
Updated 18 times since 2018 Last updated: Jun 8, 2022 Started: Nov 28, 2018 Primary completion: Oct 29, 2021 Completion: Oct 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03663335, this PHASE2 trial focuses on Kidney Transplant Rejection and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 18 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Aug 2019 · 7 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Jul 2022 [monthly]

    Completed PHASE2

▶ Show 13 earlier versions

  1. Feb 2022 — Apr 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  7. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  8. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  9. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  10. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  11. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  12. Jan 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Oct 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Aurora, United States , Baltimore, United States , Barcelona, Spain , Berlin, Germany , Bern, Switzerland , Bordeaux, France , Boston, United States , Budapest, Hungary , Buenos Aires, Argentina and 58 more locations